Theratechnologies (THTX) Competitors $1.21 -0.04 (-3.20%) (As of 10/31/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends THTX vs. TRVI, MGNX, ATYR, PYXS, INBX, RZLT, SOPH, XBIT, ZNTL, and DRUGShould you be buying Theratechnologies stock or one of its competitors? The main competitors of Theratechnologies include Trevi Therapeutics (TRVI), MacroGenics (MGNX), Atyr PHARMA (ATYR), Pyxis Oncology (PYXS), Inhibrx (INBX), Rezolute (RZLT), SOPHiA GENETICS (SOPH), XBiotech (XBIT), Zentalis Pharmaceuticals (ZNTL), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry. Theratechnologies vs. Trevi Therapeutics MacroGenics Atyr PHARMA Pyxis Oncology Inhibrx Rezolute SOPHiA GENETICS XBiotech Zentalis Pharmaceuticals Bright Minds Biosciences Theratechnologies (NASDAQ:THTX) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation. Does the media refer more to THTX or TRVI? In the previous week, Theratechnologies and Theratechnologies both had 3 articles in the media. Theratechnologies' average media sentiment score of 0.69 beat Trevi Therapeutics' score of 0.63 indicating that Theratechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theratechnologies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer THTX or TRVI? Trevi Therapeutics received 58 more outperform votes than Theratechnologies when rated by MarketBeat users. Likewise, 63.50% of users gave Trevi Therapeutics an outperform vote while only 52.73% of users gave Theratechnologies an outperform vote. CompanyUnderperformOutperformTheratechnologiesOutperform Votes2952.73% Underperform Votes2647.27% Trevi TherapeuticsOutperform Votes8763.50% Underperform Votes5036.50% Which has stronger valuation and earnings, THTX or TRVI? Theratechnologies has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheratechnologies$84.32M0.66-$23.96M-$0.19-6.37Trevi TherapeuticsN/AN/A-$29.07M-$0.39-7.55 Is THTX or TRVI more profitable? Trevi Therapeutics has a net margin of 0.00% compared to Theratechnologies' net margin of -3.75%. Theratechnologies' return on equity of 0.00% beat Trevi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Theratechnologies-3.75% N/A -4.31% Trevi Therapeutics N/A -49.92%-45.93% Which has more volatility and risk, THTX or TRVI? Theratechnologies has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Do institutionals & insiders believe in THTX or TRVI? 95.8% of Trevi Therapeutics shares are owned by institutional investors. 24.4% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts recommend THTX or TRVI? Trevi Therapeutics has a consensus price target of $7.43, suggesting a potential upside of 152.67%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Trevi Therapeutics is more favorable than Theratechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theratechnologies 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Trevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 SummaryTrevi Therapeutics beats Theratechnologies on 10 of the 17 factors compared between the two stocks. Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… Get Theratechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THTX vs. The Competition Export to ExcelMetricTheratechnologiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.64M$7.12B$5.36B$8.41BDividend YieldN/A8.77%5.22%4.20%P/E Ratio-12.1016.06131.9317.57Price / Sales0.66258.281,440.1578.36Price / CashN/A50.1639.0633.56Price / Book-2.695.674.744.57Net Income-$23.96M$151.16M$115.43M$225.42M7 Day Performance-3.20%-1.80%-0.86%-0.61%1 Month Performance-1.63%5.92%3.61%1.50%1 Year Performance34.44%39.97%38.90%32.94% Theratechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THTXTheratechnologiesN/A$1.21-3.2%N/A+35.9%$55.64M$84.32M-12.10140TRVITrevi Therapeutics3.7366 of 5 stars$3.11-3.1%$7.43+138.9%+67.2%$225.76MN/A-7.9720MGNXMacroGenics3.8749 of 5 stars$3.60-8.6%$8.11+125.3%-34.1%$225.48M$39.46M-1.64430Upcoming EarningsNews CoverageATYRAtyr PHARMA3.6874 of 5 stars$3.24-1.2%$19.25+494.1%N/A$223.60M$588,000.00-3.5656Analyst ForecastShort Interest ↓Positive NewsPYXSPyxis Oncology1.3269 of 5 stars$3.75+3.9%$9.00+140.0%+140.1%$222.83MN/A-3.0260Upcoming EarningsINBXInhibrx4.0772 of 5 stars$15.37-2.5%$27.00+75.7%+12.0%$222.50M$1.69M0.00166RZLTRezolute3.8233 of 5 stars$5.54+3.4%$11.57+108.9%+413.2%$222.35MN/A-4.1740Positive NewsSOPHSOPHiA GENETICS2.3257 of 5 stars$3.38+2.7%$6.50+92.3%-12.5%$220.98M$62.37M-3.31520Upcoming EarningsXBITXBiotech0.8047 of 5 stars$7.24+1.4%N/A+84.8%$220.52M$4.01M-6.24100News CoverageZNTLZentalis Pharmaceuticals1.9093 of 5 stars$3.10-6.6%$10.78+247.7%-83.1%$220.44MN/A-1.14160Upcoming EarningsDRUGBright Minds Biosciences1.2085 of 5 stars$49.50+5.3%N/A+3,436.6%$219.48MN/A-72.79N/AGap Up Related Companies and Tools Related Companies TRVI Competitors MGNX Competitors ATYR Competitors PYXS Competitors INBX Competitors RZLT Competitors SOPH Competitors XBIT Competitors ZNTL Competitors DRUG Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:THTX) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theratechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theratechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.